Expert Opin Drug Metab Toxicol. 2011 Sep 20.
SourceSapienza University, Regional Referral Headache Center, School of Health Sciences , Department of Medical and Molecular Sciences, Rome , Italy.
Pharmacokinetic evaluation of frovatriptan.
Negro A, Lionetto L, Casolla B, Lala N, Simmaco M, Martelletti P.SourceSapienza University, Regional Referral Headache Center, School of Health Sciences , Department of Medical and Molecular Sciences, Rome , Italy.
Abstract Introduction: Migraine is the most common painful neurological
disorder, affecting 13% of the general population. Triptans represent a powerful
pharmacological tool in acute migraine treatment, however, a significant portion
of treated patients cannot have access to this class due to possible adverse
affects. Today, a total of seven triptan molecules are available, representing a
commonly prescribed migraine treatment. Although there is a need of extensive
use of triptans, only 25% of migraine patients are using triptans. Areas
covered: This review includes triptans and evidence for the use of frovatriptan.
A systematic approach is used to discuss the pharmacodynamic and pharmacokinetic aspects of frovatriptan, considering the emerging data on the clinical efficacy of frovatriptan in the treatment of migraine and cluster headaches. The data were obtained by searching the following key words in MEDLINE: pharmacokinetic, pharmacodynamic, triptans, frovatriptan, migraine, menstrual migraine, relatively to the period 1988 - 2011.
A systematic approach is used to discuss the pharmacodynamic and pharmacokinetic aspects of frovatriptan, considering the emerging data on the clinical efficacy of frovatriptan in the treatment of migraine and cluster headaches. The data were obtained by searching the following key words in MEDLINE: pharmacokinetic, pharmacodynamic, triptans, frovatriptan, migraine, menstrual migraine, relatively to the period 1988 - 2011.
Expert opinion: Frovatriptan has been developed in order to improve safety
and efficacy of triptans. It shows a favorable tolerability and efficacy
profile, limited to 24/48-h headache recurrence, when compared with other
triptans. Preclinical data suggest that the pharmacokinetic profile of
frovatriptan may differ from other available triptans.
IN FACT, AMONG TRIPTANS, FROVATRIPTAN SHOWED THE HIGHEST POTENCY AT THE
5-HT1B RECEPTOR (8.2) AND THE LONGER HALF-LIFE (26 H). THESE PARAMETERS
DETERMINE THE CLINICAL PROPERTIES OF FROVATRIPTAN; IN PARTICULAR THE LOWEST RATE
OF HEADACHE RECURRENCE IN COMPARISON WITH OTHER TRIPTANS.
PMID:21929465[PubMed]
DISCLAIMER: The information provided on this web site is for educational and informational purposes only. It should not be used as a substitute for seeking professional care or for the diagnosis and treatment of any medical disorder. O.U.C.H. makes no claims as to the scientific/clinical validity of the information on this site OR to that of the information linked to from this site. All information taken from the internet should be discussed with a medical professional!
